MAPLE GROVE, Minn., April 5, 2011 /PRNewswire/ -- NeuroVasx announced today that the FDA has approved the cPAX Aneurysm Treatment System as a Humanitarian Use Device (HDE) for the treatment of large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat. The HDE allows for the treatment of up to 4,000 patients per year in the U.S.
Christopher Dowd, M.D., Clinical Professor of Neuro-Interventional Radiology at the University of California at San Francisco and Medical Director for NeuroVasx, Inc., said, "The large, giant and wide-neck cerebral aneurysm population continues to remain the most challenging to treat. cPAX will offer physicians an alternative solution that we believe can make a significant impact in treatment and outcome for these patients." Ricardo Hanel, M.D., PhD, Associate Professor of Neurosurgery at the Mayo Clinic in Jacksonville, Florida and Co-Principal Investigator in the cPAX Clinical Trial, states, "The longer term stability we have seen in the clinical studies using cPAX in larger aneurysms gives me great confidence in the positive impact this product will have on the care of our patients."
A cerebral aneurysm is an abnormal bulge or sac in the wall of an artery in the brain which can be caused by a number of factors including congenital defects, high blood pressure, atherosclerosis, cancer, drug use or head trauma. If a cerebral aneurysm ruptures, it can lead to a hemorrhagic stroke, or bleeding on the brain. According to the National Institutes of Health, approximately 40% of these patients do not survive the first 24 hours. The worldwide incidence of cerebral aneurysms is estimated to be 320,000 annually, approximately 200,000 of which may be treatable with intracranial surgery using minimally invasive techniques.
cPAX is a polymeric strand delivered into the aneurysm using a technique similar to currently available platinum coil technologies. cPAX, because of its soft polymeric material, is designed to achieve more complete filling of the aneurysm with the probable benefit of greater long term stability. A significant feature of cPAX in comparison to currently available technologies is that it offers the physician the ability to detach the device at any point versus a fixed detachment zone common in platinum coils. The polymeric material also allows for non-invasive CT and MRI scans with little or no artifact for more accurate patient follow-up assessment.
Eric B. Timko, President and CEO of NeuroVasx, said, "This FDA approval brings an important cutting-edge technology to a patient population that is currently underserved. We are excited to offer this treatment to patients and we look forward to working with our key physicians to bring this product to market."
About NeuroVasx, Inc.
NeuroVasx, Inc. (www.neurovasx.com) is a privately held medical device company located in Maple Grove, MN. The company is dedicated to the development and commercialization of technologies for the minimally invasive treatment of hemorrhagic and ischemic stroke. The worldwide market potential for stroke treatment devices is estimated to be over $3 billion.
|SOURCE NeuroVasx, Inc.|
Copyright©2010 PR Newswire.
All rights reserved